Publication & Citation Trends
Publications
0 total
Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Cited by 7
Semantic Scholar
Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone.
Cited by 3
Semantic Scholar
PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
Cited by 14
Semantic Scholar
PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.
Cited by 13
Semantic Scholar
Research Topics
Bone health and treatments
(48)
Prostate Cancer Treatment and Research
(47)
PARP inhibition in cancer therapy
(31)
Radiopharmaceutical Chemistry and Applications
(24)
Advanced Breast Cancer Therapies
(15)
Affiliations
Université Paris-Sud
Hebron University
University of Maryland, Baltimore
Novartis (Switzerland)
Cliniques Universitaires Saint-Luc